



Dr Subhash Wangnoo

MBBS, FRCP, DM, MD(Medicine) 31+ Years Experience

Dr Subhash Wangnoo is a top Endocrinologist in Delhi at Apollo Hospitals Delhi . Book appointment online with Dr Subhash Wangnoo at Ask Apollo.

Hospitals

Apollo Hospitals, Delhi ,

Doctor's Working
Weekdays
Tue - Fri

Doctor's Working
Hours
09:00 -09:15

Phone Icon
Call Now

Calendar Icon
Book Appointment

Overview

Dr. Subhash Wangnoo is a highly experienced Endocrinologist based in Delhi, with an impressive 31 years of practice in the field. He holds multiple qualifications, including MBBS, FRCP, DM, and MD(Med.), which reflect his extensive training and expertise in managing hormonal and metabolic disorders. Dr. Wangnoo is proficient in both English and Hindi, allowing him to effectively communicate with a diverse patient population. His practice is rooted in patient-centered care, focusing on helping individuals with conditions such as diabetes, thyroid issues, and other endocrine disorders. As an esteemed member of the Apollo healthcare network, Dr. Wangnoo is dedicated to providing the highest standard of medical care and is committed to staying current with the latest advancements in endocrinology. His approach is comprehensive, blending clinical expertise with a compassionate understanding of his patients' needs. Whether you're seeking preventive care or management of a chronic condition, Dr. Subhash Wangnoo is equipped to guide you through your healthcare journey.

Experience

- Medical Officer University Health Centre, B.H.U. Varanasi, May 1981 To September 1981.

- Senior Resident (Registrar) In Endocrinology. IMS, BHU, Varanasi October 1981 To June 1984.
- Clinical Attaché in Endocrinology, P.G.I, Chandigarh April 1982 To June 1982.
- Pool Officer in Endocrinology, IMS BHU, Varanasi, March 1984 To July 1984.
- Lecturer And Head, Department Of Endocrinology, Sher-I-Kashmir Institute Of Medical Sciences, Srinagar Kashmir July 1984 To July 1988
- Associate Professor and Head, Department Of Endocrinology, S.K.I.M.S, Srinagar, Kashmir July 1988 To March 1990
- Honorary Senior Consultant Endocrinologist, Narinder Mohan Hospital, Mohan Nagar Ghaziabad, April 1990 To January 1992
- Senior Consultant Endocrinologist at King Khalid Hospital, Saudi Arabia (Ministry Of Health), February 1992 To December 1994.
- Working in Apollo Hospitals since last Assignment

Membership

- Endocrine Society, USA
- American Diabetes Association
- Association of American College of Endocrinology
- Royal College of Physicians of London, UK
- European Association for Study of Diabetes
- Diabetes Technology and Therapeutics, USA
- International Diabetes Federation 8. Association of Physicians of India
- Endocrine Society, India
- Research Society for Study of Diabetes in India
- Indian Thyroid Society
- South Asian Association for Regional Co-operation Diabetes Society
- Indian Menopause Society
- Diabetes India

Research and Publication

- Wangnoo SK. Initiating insulin therapy in children and adolescents with type I diabetes mellitus. Indian J Endocrinol Meab.2015 Apr;19(suppl I):S68-70.

- Jindal R, Siddiqui MA, Gupta N, Wangnoo SK. Prevalence of glucose intolerance at 6 weeks postpartum in Indian women with gestational diabetes mellitus, *Diabetes Metab Syndr*.2015 Jul-Sep;9(3):143-6.
- Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, chandalia HB, Chowdhury S, Jothydev K, Kumar PK, V MS, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundram A, Unnikrishnan AG, Wangnoo SK. Forum for Injection Technique(FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015. *Indian J Endocrinol Metab*.2015 May-Jun;19(3):317-31.
- Wangnoo SK, Chowdhury S, Rao PV. Treating to target in type 2 diabetes: the BEGIN trial programme. *J Assoc Physicians India*. 2014 Jan;62(I Suppl):21-6.
- Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, Wangnoo SK, Kumar A, Kalra S, Unnikrishnan AG, Sharma SK, Rao PV, Akhtar S, Shetty RV, Das AK; DiabCare India 2011 Study Group. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. *Indian J Endocrinol Metab*. 2014 May;18(3):370-8.
- Kesavadev J, Sadikot S, Wangnoo S, Kannampilly J, Saboo B, Aravind SR, Kalra S, Makkar BM, Maji D, Saikia M, Anjana RM, Rajput R, Singh SK, Shah S, Dhruv U, Vishwanathan V. Consensus guidelines for glycemic monitoring in type 1/type 2 and GDM. *Diabetes Metab syndr*.2014Jul-Sep;8(3):187-95.
- Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. *Indian J Endocrinol Metab*.2014Mar;18(2):166-74.
- Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Clinical experience of switching from glargine or neutral protamine hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the AI chieve study. *Indian J Endocrinol Metab*, 2014 Sep;18(5):715-20.
- Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. *Indian J Endocrinol Metab*.2014 Mar;18(2):166-74.
- Radhika Jindal, Ayesha Ahmad, Mohammad Asim Siddiqui, Inderpal Singh Kochar, Subhash Kumar Wangnoo. Novel mutation .597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism. *Diabetes Metab syndr*.2014 Jan-Mar;8(1):45-7.
- Wangnoo SK, Bader G, Gawai A, Singh S. Effectiveness and Tolerability of Vildagliptin in Indian Patients with Type 2 Diabetes Mellitus: Results From Edge-A Renal-World Observational Study *IJCP*.2013;24(6):537-42.
- Jindal R, gupta N, Siddiqui MA, Wangnoo SK, Post-Prandial Hyperglycemia. *JIACM*.2013;14(3-4);242-246.

- Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Goke R, Marquez Rodriguez E, Nilson PM, Pagkalos E, Penforia A, Schaper NC, Wangnoo SK, Kothny W, Bader G. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). *Int J Clin Pract.* 2013 Oct; 67(10):947-56.
- Wangnoo SK, Maji D, Das AK, Rao PV, Moses A, Sethi B, Unnikrishnan AG, Kalra S, Balaji V, Bantwal G, Kesavadev J, Jain SM, Dharmalingam M. Barriers and solutions to diabetes management: An Indian perspective. *Indian J Endocrinol Metab.* 2013 Jul;17(4):594-601.
- Niti Agarwal, SK Wangnoo, Asim Siddiqui, Mukul Gupta. primary thyroid Lymphoma: A Series of Two Cases and Review of Literature. *JAPI* 2013;(61)496-498.
- Gokulnath, Sahay M, Kalra S, Vishwanathan V, Zargar AH, Talwalkar PG, Wangnoo SK, Maji D, Kumar GV, Sharma RK, Chafekar D, Mohan B, Bantwal G, Bansali A, Sahni JS. Protocol of an observational study to evaluate diabetic nephropathy through detection of microalbuminuria in Indian patients. *Indian J Endocrinol Metab.* 2013 May;17(3):496-504.
- Zubair Ahmed, Jamal Ahmad, Abida Malik, Mohammad Asim Siddiqui, Sibhash Kumar Wangnoo, Cathepsin-d, Adiponectin, TNF-alpha, IL-6 and hsCRP plasma levels in subjects with diabetic foot and possible correlation with clinical variables: a multicentric study. Ahmad J, Zubair M, Malik A, Siddiqui MA, Wangnoo SK. *Foot (Edinb).* 2012 Sep;22(3):1949-9. *EPup* 2012 May 3.
- Unnikrishnan AG, Wangnoo SK, Joshi SR, Banerjee S, Kumar A, Kalra S, Channabasavaiah R, Shetty R. Physician perceptions and practices in management of diabetes in India: Results from the IMPROVE Control program. *Indian J Endocrinol Metab.* 2012 Dec;16(suppl 2):S428-9.
- Jindal R, Ahmad A, Siddiqui MA, Wangnoo SK. What the future holds for gliptins. *Indian J Endocrinol Metab.* 2012 Dec;16(suppl 2): S242-4.
- Ahmad A, Siddiqui MA, Goyal A, Wangnoo SK. *BMJ Case Rep.* 2012 Jul 18:2012.
- Mohan V, Unnikrishnan R, Thomas N, Bhansali A, Wangnoo SK, Thomas K. Pneumococcal injections and immunization in diabetic patients. *J Postgrad Med.* 2011 Jan-Mar;57(1):78-81.
- M. Siddiqui, M. Gupta, V. Kaul, S.K. Wangnoo. Improvement in Glycemic control daily injections in diabetes in pregnancy. *Diabetes Technology and Therapeutics* Volume 13, Number 2, 2011;P273-274.
- Mohammad Siddiqui, Mukul Gupta, Subhash Wangnoo & Jamal Ahmad. Safety profile of Vildagliptin in clinical practice: 2-year data from 2 Tertiary hospitals. *Endocrine Abstracts* (2011)25P128.
- Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta, Nitin Gupta, Subhash Kumar Wangnoo. Prevalence of Abnormal Metabolic Parameters in Overweight Non-Diabetic children. *Endocr Rev* June 2011;32, P3-421.
- Mukul Gupta, Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta, Nitin Gupta, Subhash Kumar Wangnoo. Durability of Effects of Exenatide Treatment of Glycemic Control, Body Weight, hsCRP, Lipid

Concentrations and Bone Mineral Density. Endocr Rev, Vol.32:P3-492.

- Mohammad Asim Siddiqui, Mukul gupta, Nitin Gupta, Subhash Kumar Wangnoo. Improvements in Metabolic Parameters along with Glycemic Status in Newly Diagnosed Obese North Indian Type 2 Diabetes on Liraglutide Addition to Metformin Monotherapy. Diabetes July 2011 60; A6092292 PO.
- Mohammad Asim Siddiqui, SK Wangnoo. Metabolic Phenotype in brother's of women with polycystic ovarian syndrome. Endocrine Abstracts.P165(2010). Vol21.
- M Gupta, MA Siddiqui, SK Wangnoo. Risk Awareness of Conversion of Gestational Diabetes Mellitus into Diabetes among women with Previous History of GDM and Treating General Practitioners Endocrine Reviews, Supplement 1, June 2010, 31(3); S1443.
- M.A. Siddiqui, M gupta, SK Wangnoo, J Ahmad, Clinical And Metabolic Heterogeneity in Obese and Lean Women With Polycystic Ovarian Disease. Endocrine Reviews, Supplement 1, June 2010, 31(3):S2108.
- S.k.Wangnoo, M.A. Siddiqui, M. Gupta. Effect of Long-Acting Obstructive Sandostatin Analogs On Blood Glucose Profiles in Patient with Acromegaly. Endocrine Reviews, Supplement 1, June 2010, 31(3):S2256.
- S.K. Wangnoo, M.A. Siddiqui, M. gupta, M.S.Kanwar. Obstructive Sleep Apnoea and metabolic abnormalities in type 2 diabetes, Diabetologia (2010)53:(suppl I)S1-S556.
- N Shamra , H. Dua, MA Siddiqui, M Gupta, SK Wangnoo. Prevalence of 25 Hydroxyvitamin D Deficiency in Newly Diagnosed Multiple Myeloma patients in a tertiary Care setting. Osteoporosis International (2010). Volume 21. Supplements 5.
- Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; consensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physician India.2009 Feb; 57:163-70.
- Jadzinsky M, Pfitzner A, Paz-Pachoo E, XU Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes obes Metab. 2009Jun;11(6):611-22.
- Govalkar RM, Wangnoo SK. Localized genital kaposi sarcoma. ANN Saudi Med.1994 Nov;14(6):517-8.
- 36. Koul R, Saxena R, Wangnoo S. Myelomyopathy and thymotoxicosis. J Assoc Physician India. 1989 Nov 37(11):721 Siddiqui MA, Wangnoo SK, Selective IgG subclass antibody response to insulin in diabetic receiving animal insulin replacement therapy. Int Arch Allergy Appl Immunol. 1989;89(1):49-53.

Frequently Asked Questions

1. Where does Dr. Subhash Wangnoo practice?

Dr. Subhash Wangnoo's practice is located at Apollo Hospitals, Delhi. This hospital offers comprehensive healthcare services and advanced medical expertise.

2. Who is Dr. Subhash Wangnoo?

Dr Subhash Wangnoo is a renowned Endocrinologist with over 31 years of experience. He practices in Delhi at Apollo Hospitals Delhi. Dr Subhash Wangnoo holds a degree in MBBS, FRCP, DM, MD(Medicine). He provides treatments including Insulin Therapy, Thyroid Hormone Replacement, Bone Density Treatments. He specializes in treating conditions like Diabetes Mellitus, Thyroid Disorders, Osteoporosis.

3. What is Dr. Subhash Wangnoo's specialization?

Dr Subhash Wangnoo specializes in Endocrinology. He has expertise in treating conditions such as Diabetes Mellitus, Thyroid Disorders, Osteoporosis. His key treatments include Insulin Therapy, Thyroid Hormone Replacement, Bone Density Treatments.

4. What are Dr. Subhash Wangnoo's medical qualifications?

Dr Subhash Wangnoo holds MBBS, FRCP, DM, MD(Medicine), reflecting his comprehensive education in the field of Endocrinology.

5. What is Dr. Subhash Wangnoo's experience?

Dr. Subhash Wangnoo has 31 years of experience in endocrinology.

6. Why do patients consult Dr. Subhash Wangnoo?

Patients seek Dr. Subhash Wangnoo's expertise for conditions including lactation counseling, hypertension treatment, and thyroid swelling. For a complete list of his areas of specialization, please refer to his profile.

7. What is patient feedback on Dr. Subhash Wangnoo?

Dr. Subhash Wangnoo has received positive feedback from 10 patients, including 9 detailed reviews. To access these testimonials, please contact the hospital directly.

8. Who is an endocrinologist?

Endocrinologists are medical doctors specializing in the diagnosis and treatment of endocrine system disorders. Their expertise encompasses hormone-related illnesses affecting glands like the thyroid, pituitary, and pancreas.

9. What symptoms necessitate an endocrinology consultation?

Consult an endocrinologist if you experience symptoms suggestive of hormonal imbalances, such as unexplained weight fluctuations, acne, hirsutism (in women), infertility, fatigue, significant hair loss, intolerance to temperature changes, voice alterations, and other related issues. These symptoms may indicate underlying endocrine disorders requiring specialist care.

10. What conditions are treated by an endocrinologist?

Endocrinologists manage various hormonal disorders, including hypothyroidism, hyperthyroidism, insulin imbalances (diabetes), gigantism, dwarfism, Cushing's syndrome, pituitary gland dysfunction, polycystic ovary syndrome (PCOD), and infertility.